Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.

Identifieur interne : 001A12 ( Main/Exploration ); précédent : 001A11; suivant : 001A13

Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.

Auteurs : R A Johnson [États-Unis] ; X. Wang ; X L Ma ; S M Huong ; E S Huang

Source :

RBID : pubmed:11390604

Descripteurs français

English descriptors

Abstract

Infection of quiescent fibroblasts with human cytomegalovirus (HCMV) was found to cause a rapid activation of cellular phosphatidylinositol 3-kinase (PI3-K). Maximum PI3-K activation occurred from 15 to 30 min postinfection. This activation was transient, and by 2 h postinfection (hpi), PI3-K activity had declined to preinfection levels. However, at 4 hpi, a second tier of PI3-K activation was detected, and PI3-K activity remained elevated relative to that of mock-infected cells for the remainder of infection. The cellular kinases Akt and p70S6K and the transcription factor NF-kappaB were activated in a PI3-K-dependent manner at similar times following HCMV infection. Analysis using UV-irradiated virus indicated that no viral protein synthesis was necessary for the first phase of PI3-K activation, but viral protein expression was required for the second tier of PI3-K activation. Treatment of infected fibroblasts with LY294002, a potent and specific inhibitor of PI3-K kinase activity, caused a 4-log decrease in viral titers. LY294002 did not inhibit viral entry, but it did decrease viral immediate-early gene expression. In addition, the protein levels of two viral early genes required for DNA replication, UL84 and UL44, were significantly lower in the presence of LY294002. Furthermore, viral DNA replication was strongly inhibited by LY294002 treatment. This inhibition of viral DNA replication could be reversed by adding back the products of PI3-K activity (PI-3,4-P(2) and PI-3,4,5-P(3)), demonstrating that the effect of LY294002 on the viral life cycle was specifically due to the inhibition of PI3-K activity. These results are the first to suggest that PI3-K mediates HCMV-induced activation of host cell mitogenic pathways. They also provide strong evidence that PI3-K activation is important for initiation of viral DNA replication and completion of the viral lytic life cycle.

DOI: 10.1128/JVI.75.13.6022-6032.2001
PubMed: 11390604
PubMed Central: PMC114318


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.</title>
<author>
<name sortKey="Johnson, R A" sort="Johnson, R A" uniqKey="Johnson R" first="R A" last="Johnson">R A Johnson</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
<settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wang, X" sort="Wang, X" uniqKey="Wang X" first="X" last="Wang">X. Wang</name>
</author>
<author>
<name sortKey="Ma, X L" sort="Ma, X L" uniqKey="Ma X" first="X L" last="Ma">X L Ma</name>
</author>
<author>
<name sortKey="Huong, S M" sort="Huong, S M" uniqKey="Huong S" first="S M" last="Huong">S M Huong</name>
</author>
<author>
<name sortKey="Huang, E S" sort="Huang, E S" uniqKey="Huang E" first="E S" last="Huang">E S Huang</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11390604</idno>
<idno type="pmid">11390604</idno>
<idno type="doi">10.1128/JVI.75.13.6022-6032.2001</idno>
<idno type="pmc">PMC114318</idno>
<idno type="wicri:Area/Main/Corpus">001A13</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A13</idno>
<idno type="wicri:Area/Main/Curation">001A13</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A13</idno>
<idno type="wicri:Area/Main/Exploration">001A13</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.</title>
<author>
<name sortKey="Johnson, R A" sort="Johnson, R A" uniqKey="Johnson R" first="R A" last="Johnson">R A Johnson</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
<settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
</affiliation>
</author>
<author>
<name sortKey="Wang, X" sort="Wang, X" uniqKey="Wang X" first="X" last="Wang">X. Wang</name>
</author>
<author>
<name sortKey="Ma, X L" sort="Ma, X L" uniqKey="Ma X" first="X L" last="Ma">X L Ma</name>
</author>
<author>
<name sortKey="Huong, S M" sort="Huong, S M" uniqKey="Huong S" first="S M" last="Huong">S M Huong</name>
</author>
<author>
<name sortKey="Huang, E S" sort="Huang, E S" uniqKey="Huang E" first="E S" last="Huang">E S Huang</name>
</author>
</analytic>
<series>
<title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint>
<date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cell Line (MeSH)</term>
<term>Chromones (pharmacology)</term>
<term>Cytomegalovirus (physiology)</term>
<term>DNA Replication (MeSH)</term>
<term>Gene Expression Regulation, Viral (drug effects)</term>
<term>Humans (MeSH)</term>
<term>Morpholines (pharmacology)</term>
<term>NF-kappa B (metabolism)</term>
<term>Phosphatidylinositol 3-Kinases (physiology)</term>
<term>Protein-Serine-Threonine Kinases (MeSH)</term>
<term>Proto-Oncogene Proteins (metabolism)</term>
<term>Proto-Oncogene Proteins c-akt (MeSH)</term>
<term>Ribosomal Protein S6 Kinases (metabolism)</term>
<term>Sirolimus (pharmacology)</term>
<term>Up-Regulation (MeSH)</term>
<term>Virus Replication (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>4H-1-Benzopyran-4-ones (pharmacologie)</term>
<term>Cytomegalovirus (physiologie)</term>
<term>Facteur de transcription NF-kappa B (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Lignée cellulaire (MeSH)</term>
<term>Morpholines (pharmacologie)</term>
<term>Phosphatidylinositol 3-kinases (physiologie)</term>
<term>Protein-Serine-Threonine Kinases (MeSH)</term>
<term>Protéines proto-oncogènes (métabolisme)</term>
<term>Protéines proto-oncogènes c-akt (MeSH)</term>
<term>Ribosomal Protein S6 Kinases (métabolisme)</term>
<term>Régulation de l'expression des gènes viraux (effets des médicaments et des substances chimiques)</term>
<term>Régulation positive (MeSH)</term>
<term>Réplication de l'ADN (MeSH)</term>
<term>Réplication virale (MeSH)</term>
<term>Sirolimus (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>NF-kappa B</term>
<term>Proto-Oncogene Proteins</term>
<term>Ribosomal Protein S6 Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Chromones</term>
<term>Morpholines</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Gene Expression Regulation, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Régulation de l'expression des gènes viraux</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Facteur de transcription NF-kappa B</term>
<term>Protéines proto-oncogènes</term>
<term>Ribosomal Protein S6 Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>4H-1-Benzopyran-4-ones</term>
<term>Morpholines</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Cytomegalovirus</term>
<term>Phosphatidylinositol 3-kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Cytomegalovirus</term>
<term>Phosphatidylinositol 3-Kinases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cell Line</term>
<term>DNA Replication</term>
<term>Humans</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Proto-Oncogene Proteins c-akt</term>
<term>Up-Regulation</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Régulation positive</term>
<term>Réplication de l'ADN</term>
<term>Réplication virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Infection of quiescent fibroblasts with human cytomegalovirus (HCMV) was found to cause a rapid activation of cellular phosphatidylinositol 3-kinase (PI3-K). Maximum PI3-K activation occurred from 15 to 30 min postinfection. This activation was transient, and by 2 h postinfection (hpi), PI3-K activity had declined to preinfection levels. However, at 4 hpi, a second tier of PI3-K activation was detected, and PI3-K activity remained elevated relative to that of mock-infected cells for the remainder of infection. The cellular kinases Akt and p70S6K and the transcription factor NF-kappaB were activated in a PI3-K-dependent manner at similar times following HCMV infection. Analysis using UV-irradiated virus indicated that no viral protein synthesis was necessary for the first phase of PI3-K activation, but viral protein expression was required for the second tier of PI3-K activation. Treatment of infected fibroblasts with LY294002, a potent and specific inhibitor of PI3-K kinase activity, caused a 4-log decrease in viral titers. LY294002 did not inhibit viral entry, but it did decrease viral immediate-early gene expression. In addition, the protein levels of two viral early genes required for DNA replication, UL84 and UL44, were significantly lower in the presence of LY294002. Furthermore, viral DNA replication was strongly inhibited by LY294002 treatment. This inhibition of viral DNA replication could be reversed by adding back the products of PI3-K activity (PI-3,4-P(2) and PI-3,4,5-P(3)), demonstrating that the effect of LY294002 on the viral life cycle was specifically due to the inhibition of PI3-K activity. These results are the first to suggest that PI3-K mediates HCMV-induced activation of host cell mitogenic pathways. They also provide strong evidence that PI3-K activation is important for initiation of viral DNA replication and completion of the viral lytic life cycle.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11390604</PMID>
<DateCompleted>
<Year>2001</Year>
<Month>06</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>75</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2001</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J Virol</ISOAbbreviation>
</Journal>
<ArticleTitle>Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>6022-32</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Infection of quiescent fibroblasts with human cytomegalovirus (HCMV) was found to cause a rapid activation of cellular phosphatidylinositol 3-kinase (PI3-K). Maximum PI3-K activation occurred from 15 to 30 min postinfection. This activation was transient, and by 2 h postinfection (hpi), PI3-K activity had declined to preinfection levels. However, at 4 hpi, a second tier of PI3-K activation was detected, and PI3-K activity remained elevated relative to that of mock-infected cells for the remainder of infection. The cellular kinases Akt and p70S6K and the transcription factor NF-kappaB were activated in a PI3-K-dependent manner at similar times following HCMV infection. Analysis using UV-irradiated virus indicated that no viral protein synthesis was necessary for the first phase of PI3-K activation, but viral protein expression was required for the second tier of PI3-K activation. Treatment of infected fibroblasts with LY294002, a potent and specific inhibitor of PI3-K kinase activity, caused a 4-log decrease in viral titers. LY294002 did not inhibit viral entry, but it did decrease viral immediate-early gene expression. In addition, the protein levels of two viral early genes required for DNA replication, UL84 and UL44, were significantly lower in the presence of LY294002. Furthermore, viral DNA replication was strongly inhibited by LY294002 treatment. This inhibition of viral DNA replication could be reversed by adding back the products of PI3-K activity (PI-3,4-P(2) and PI-3,4,5-P(3)), demonstrating that the effect of LY294002 on the viral life cycle was specifically due to the inhibition of PI3-K activity. These results are the first to suggest that PI3-K mediates HCMV-induced activation of host cell mitogenic pathways. They also provide strong evidence that PI3-K activation is important for initiation of viral DNA replication and completion of the viral lytic life cycle.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>R A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>X L</ForeName>
<Initials>XL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huong</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>E S</ForeName>
<Initials>ES</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 CA019014</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI47468</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 AI007419</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>2T32 AI07419</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA19014</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>31M2U1DVID</RegistryNumber>
<NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D019893">Ribosomal Protein S6 Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004261" MajorTopicYN="N">DNA Replication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015967" MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017346" MajorTopicYN="Y">Protein-Serine-Threonine Kinases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019893" MajorTopicYN="N">Ribosomal Protein S6 Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2001</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2001</Year>
<Month>6</Month>
<Day>29</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2001</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">11390604</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.75.13.6022-6032.2001</ArticleId>
<ArticleId IdType="pmc">PMC114318</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>FEBS Lett. 1997 Jun 23;410(1):78-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9247127</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gen Virol. 1997 Aug;78 ( Pt 8):1993-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9266999</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Biochem Sci. 1997 Sep;22(9):355-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9301337</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1997 Nov 14;272(46):29167-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9360994</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 1998 Jul 23;17(3):313-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9690513</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Biochem. 1998;67:481-507</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9759495</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1998 Nov 6;273(45):29411-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9792644</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):429-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9892650</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1999 Apr 15;162(8):4806-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10202024</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1999 May;19(5):3607-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10207084</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antiviral Res. 1999 Apr;41(3):101-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10320043</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1999 Jun;19(6):4279-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10330169</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Biol. 1999 Jun 3;9(11):601-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10359702</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1999 Jul;19(7):4729-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10373522</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1999 Sep 2;401(6748):86-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10485711</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1996 Jun;70(6):3339-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8648663</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1993 Apr 1;150(7):2794-804</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8454856</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1993 May 5;268(13):9478-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7683653</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1993 Oct;13(10):6089-101</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8413211</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1993 Dec;67(12):6979-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8230421</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 1993 Dec 30;197(3):1505-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8280168</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1994 Mar 18;263(5153):1609-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8128248</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1996 Aug;16(8):4117-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8754810</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12 Suppl 1:S1-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8680897</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Biochem Sci. 1996 May;21(5):181-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8871403</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FEBS Lett. 1996 Dec 16;399(3):333-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8985174</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1997 Feb 6;385(6616):544-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9020362</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1997 Mar;17(3):1595-606</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9032287</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3627-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9108028</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1997 Jun;71(6):4638-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9151857</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 1997 May 12;231(2):239-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9168886</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1997 May 15;16(10):2783-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9184223</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1997 Jul;71(7):5051-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9188570</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1997 Jun 12;387(6634):673-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9192891</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1997 Aug;17(8):4406-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9234699</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1994 May 1;54(9):2419-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8162590</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 1994 Jul;202(1):247-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8009835</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1994 Aug 18;370(6490):527-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8052307</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1994 Dec 22-29;372(6508):739-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7997261</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1995 Jan 13;270(2):815-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7822316</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virus Res. 1994 Dec;34(3):191-206</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7856311</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1995 Jun 2;81(5):727-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7774014</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1995 Aug 4;269(5224):690-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7624799</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1995 Sep;69(9):5391-400</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7636984</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1995 Sep 8;270(36):21396-403</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7545671</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1995 Dec;69(12):7960-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7494309</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1995 Nov 1;14(21):5279-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7489717</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1996 May 15;15(10):2442-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8665852</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1996 May 31;85(5):621-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8646770</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Immunol. 1996;14:649-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8717528</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 1996 Jul 18;13(2):343-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8710373</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12536-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10535957</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 1999 Nov 1;18(45):6094-103</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10557100</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Cell Res. 1999 Nov 25;253(1):100-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10579915</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Cell Res. 1999 Nov 25;253(1):210-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10579924</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Cell Res. 1999 Nov 25;253(1):239-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10579926</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2000 Feb;74(3):1158-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10627526</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2000 Feb 1;164(3):1355-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10640750</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2000 Mar;20(5):1626-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10669740</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem J. 2000 Mar 15;346 Pt 3:561-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10698680</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem J. 2000 Jun 1;348 Pt 2:351-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10816429</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gen Virol. 2001 Mar;82(Pt 3):493-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11172089</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1973 Dec;12(6):1473-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">4128379</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1975 Aug;16(2):298-310</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">168404</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1977 Oct;24(1):13-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20515</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1981 Feb;78(2):1237-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6112742</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antimicrob Agents Chemother. 1983 Oct;24(4):518-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6316844</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1989 Dec 20;8(13):4251-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2556267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1990 Jan;64(1):9-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2152837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1990 Feb 2;247(4942):561-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1689075</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1991 Apr 5;65(1):83-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1849461</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1991 Aug 25;266(24):15771-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1874734</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1992 Feb;66(2):1098-108</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1309892</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antimicrob Agents Chemother. 1991 Nov;35(11):2191-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1666492</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1992 Jun 26;69(7):1227-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1377606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1992 Aug 7;70(3):419-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1322797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 1992 Aug 14;186(3):1315-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1380801</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1992 Oct;12(10):4364-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1328853</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1107-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8381532</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1993 Mar 12;72(5):767-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7680959</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Caroline du Nord</li>
</region>
<settlement>
<li>Chapel Hill (Caroline du Nord)</li>
</settlement>
<orgName>
<li>Université de Caroline du Nord à Chapel Hill</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Huang, E S" sort="Huang, E S" uniqKey="Huang E" first="E S" last="Huang">E S Huang</name>
<name sortKey="Huong, S M" sort="Huong, S M" uniqKey="Huong S" first="S M" last="Huong">S M Huong</name>
<name sortKey="Ma, X L" sort="Ma, X L" uniqKey="Ma X" first="X L" last="Ma">X L Ma</name>
<name sortKey="Wang, X" sort="Wang, X" uniqKey="Wang X" first="X" last="Wang">X. Wang</name>
</noCountry>
<country name="États-Unis">
<region name="Caroline du Nord">
<name sortKey="Johnson, R A" sort="Johnson, R A" uniqKey="Johnson R" first="R A" last="Johnson">R A Johnson</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A12 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A12 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:11390604
   |texte=   Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:11390604" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020